Efficacy and Safety of Different Doses of Indacaterol

Inclusion criteria

• Patients with a diagnosis of asthma, and:

• Receiving daily treatment with inhaled corticosteroid in a regimen that has been stable for at least a month prior to screening
• Prebronchodilator forced expiratory volume in 1 second (FEV1) at screening ≥50 and ≤90% of predicted normal
• An increase of ≥12% and ≥200 mL in FEV1 over prebronchodilator value within 30 minutes after inhaling albuterol

Exclusion criteria

• Smoking history >10 pack-years
• Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)
• Patients with seasonal allergy whose asthma is likely to deteriorate during the study period
• Patients who have experienced a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening
• Patients who have had an intubation for a severe asthma exacerbation
• Patients who have had an emergency room visit for an asthma attack/asthma exacerbation within 6 weeks prior to screening
• Patients who have had a respiratory tract infection within 6 weeks prior to screening
• Patients with concomitant pulmonary disease
• Patients with diabetes Type I or uncontrolled diabetes Type II
• Any patient with lung cancer or a history of lung cancer
• Patients with a history of certain cardiovascular comorbid conditions
• Patients who have ever received or are currently receiving omalizumab or chronic oral corticosteroid therapy

Other protocol-defined inclusion/exclusion criteria may apply